New drug combo aims to tackle stubborn hepatitis d
NCT ID NCT07128550
First seen Jun 25, 2026 · Last updated Jul 14, 2026 · Updated 3 times
Summary
This Phase 3 trial tests whether a combination of two drugs, tobevibart and elebsiran, can suppress hepatitis D virus in adults who are still infected despite taking bulevirtide. About 150 participants will receive the combo as injections. The main goal is to see if the virus becomes undetectable in the blood after 24 weeks of treatment and stays undetectable 24 weeks after treatment ends.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tobevibart and Elebsiran (two drugs given as injections)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with chronic hepatitis D who are not responding to current therapy.
- What could go wrong
- This is an early Phase 3 trial with only 150 participants, so results may not apply to everyone. The drugs could cause side effects, and the virus might not be fully cleared.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VIRAL HEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigative Site
Innsbruck, 6020, Austria
-
Investigative Site
Vienna, 1090, Austria
-
Investigative Site
Bobigny, 93009, France
-
Investigative Site
Clichy, 92110, France
-
Investigative Site
Créteil, 94000, France
-
Investigative Site
Le Chesnay, 78150, France
-
Investigative Site
Limoges, 87000, France
-
Investigative Site
Lyon, 69004, France
-
Investigative Site
Montpellier, 34295, France
-
Investigative Site
Pessac, 33604, France
-
Investigative Site
Rennes, 35033, France
-
Investigative Site
Toulouse, 31059, France
-
Investigative Site
Villejuif, 94804, France
-
Investigative Site
Berlin, 13353, Germany
-
Investigative Site
Essen, 45147, Germany
-
Investigative Site
Frankfurt am Main, 60590, Germany
-
Investigative Site
Hanover, 30625, Germany
-
Investigative Site
Bergamo, 24127, Italy
-
Investigative Site
Foggia, 71122, Italy
-
Investigative Site
Milan, 20089, Italy
-
Investigative Site
Milan, 20122, Italy
-
Investigative Site
Pisa, 56124, Italy
-
Investigative Site
Torino, 10122, Italy
-
Investigative Site
Torino, 10126, Italy
-
Investigative Site
Bucharest, 021105, Romania
-
Investigative Site
Bucharest, 022328, Romania
-
Investigative Site
Bucharest, 030303, Romania
-
Investigative Site
Craiova, 200073, Romania
-
Investigative Site
Barcelona, 08035, Spain
-
Investigative Site
Barcelona, 08036, Spain
-
Investigative Site
Madrid, 28007, Spain
-
Investigative Site
Madrid, 28046, Spain
-
Investigative Site
Santander, 39008, Spain
-
Investigative Site
London, E1 1FR, United Kingdom
-
Investigative Site
London, SE5 9NU, United Kingdom
-
Investigative Site
London, W2 1NY, United Kingdom
-
Investigative Site
Manchester, M8 5RB, United Kingdom
-
Investigative Site
Nottingham, NG7 2UH, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hepatitis b drug showdown: which is safer for kidneys?
- New ultrasound technique aims to better measure liver health
- New Free-Breathing MRI could make liver scans easier for kids
- New MRI scan could replace liver biopsies
- New drug duo aims to control hard-to-treat hepatitis delta
- New drug duo takes on rare liver virus in head-to-head trial